EMEA-001757-PIP02-15-M03

Table of contents

Key facts

Active substance
Copanlisib
Therapeutic area
Oncology
Decision number
P/0385/2022
PIP number
EMEA-001757-PIP02-15-M03
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
  • Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
  • Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Bayer AG
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating